These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20035793)

  • 1. Nest building performance following MPTP toxicity in mice.
    Sager TN; Kirchhoff J; Mørk A; Van Beek J; Thirstrup K; Didriksen M; Lauridsen JB
    Behav Brain Res; 2010 Apr; 208(2):444-9. PubMed ID: 20035793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins.
    Petzinger GM; Fisher B; Hogg E; Abernathy A; Arevalo P; Nixon K; Jakowec MW
    J Neurosci Res; 2006 Feb; 83(2):332-47. PubMed ID: 16385585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for a dissociation between MPTP toxicity and tyrosinase activity based on congenic mouse strain susceptibility.
    Hofele K; Sedelis M; Auburger GW; Morgan S; Huston JP; Schwarting RK
    Exp Neurol; 2001 Mar; 168(1):116-22. PubMed ID: 11170726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotection in Parkinson models varies with toxin administration protocol.
    Anderson DW; Bradbury KA; Schneider JS
    Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
    Leng A; Mura A; Hengerer B; Feldon J; Ferger B
    Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aging of the dopaminergic system and motor behavior in mice intoxicated with the parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Schumm S; Sebban C; Cohen-Salmon C; Callebert J; Launay JM; Golmard JL; Boussicault L; Petropoulos I; Hild A; Rousselet E; Prigent A; Friguet B; Mariani J; Hirsch EC
    J Neurochem; 2012 Sep; 122(5):1032-46. PubMed ID: 22708926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice.
    Ookubo M; Yokoyama H; Kato H; Araki T
    Mol Cell Endocrinol; 2009 Nov; 311(1-2):62-8. PubMed ID: 19631714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Yasuda Y; Shinagawa R; Yamada M; Mori T; Tateishi N; Fujita S
    Brain Res; 2007 Mar; 1138():196-202. PubMed ID: 17275793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.
    Gibrat C; Saint-Pierre M; Bousquet M; Lévesque D; Rouillard C; Cicchetti F
    J Neurochem; 2009 Jun; 109(5):1469-82. PubMed ID: 19457163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
    Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
    Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
    Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. H MRS identifies lactate rise in the striatum of MPTP-treated C57BL/6 mice.
    Koga K; Mori A; Ohashi S; Kurihara N; Kitagawa H; Ishikawa M; Mitsumoto Y; Nakai M
    Eur J Neurosci; 2006 Feb; 23(4):1077-81. PubMed ID: 16519673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson's disease.
    Geng X; Tian X; Tu P; Pu X
    Eur J Pharmacol; 2007 Jun; 564(1-3):66-74. PubMed ID: 17359968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
    Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
    Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
    Mori A; Ohashi S; Nakai M; Moriizumi T; Mitsumoto Y
    Neurosci Res; 2005 Mar; 51(3):265-74. PubMed ID: 15710490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MPTP treatment in mice does not transmit and cause Parkinsonian neurotoxicity in non-treated cagemates through close contact.
    Lau YS; Novikova L; Roels C
    Neurosci Res; 2005 Aug; 52(4):371-8. PubMed ID: 15936837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse basal ganglia.
    Fisher BE; Petzinger GM; Nixon K; Hogg E; Bremmer S; Meshul CK; Jakowec MW
    J Neurosci Res; 2004 Aug; 77(3):378-90. PubMed ID: 15248294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy).
    Stefanova N; Puschban Z; Fernagut PO; Brouillet E; Tison F; Reindl M; Jellinger KA; Poewe W; Wenning GK
    Acta Neuropathol; 2003 Aug; 106(2):157-66. PubMed ID: 12764627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
    Schmidt N; Ferger B
    Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.